ABBV: Call Open Interest Soars at $230 as Legal and Earnings Moves Shape the Path Forward

• Current price at $212.96, up 0.65% from the open.
• Options activity shows a strong call bias at the $230 strike expiring next Friday.
• JPMorgan lifts its price target to $260, calling this a buying opportunity.

If you’ve been watching the options market today, you’ve probably noticed a clear shift toward the upside. ABBV is trading just above its 30-day moving average and is hovering near the upper Bollinger Band. More importantly, call open interest has surged at the $230 strike for the next Friday expiration — a sign that institutional players are bracing for a potential breakout. This isn’t just noise. It’s a signal.

Bullish Sentiment at $230 and $220 Strikes

Options market activity tells a story of cautious optimism. For this Friday’s expiration, the top call options have open interest at $215, $217.5, and $220 — but it’s next Friday’s data that’s more telling. The $230 strike has 2171 contracts of open interest, and the $220 strike isn’t far behind at 1644 contracts. That’s a lot of capital betting on a move above $220–$230. On the put side, the largest open interest at $190 and $200 suggests a floor near $200 is being watched closely.

But there’s no major whale activity today — no massive block trades to tip the balance. That means the current price action is more likely driven by a combination of news and positioning. The market is reacting, not being manipulated.

Earnings, Legal, and the Price Target That Matters

Now, let’s connect the dots with the recent news. AbbVie cut its earnings guidance for 2026 to $13.96–$14.16 EPS from a previous $14.56 consensus — and that’s not great. But it’s not all bad. The company is aggressively defending its revenue by challenging the 340B program in court, which could limit the number of patients who get discounted drugs. That’s a defensive move that could help preserve margins in a high-cost, low-growth sector.

Meanwhile, JPMorgan raised its price target to $260, calling the stock a buying opportunity after the recent dip. And with a 3.3% dividend yield and a 5.5% raise in that dividend, AbbVie is showing it’s a company that values its shareholders — even while it navigates regulatory and competitive headwinds.

Trades to Consider: Calls at $230 and a Core Buy at $212.50

If you’re bullish but cautious, the ABBV20260417C230 call option (expiring April 17th) looks attractive. With open interest at 2171, it’s the most liquid of the key bullish strikes and gives you exposure to a potential breakout above $230. If ABBV stays above $213.50, this strike could see significant value.

For stock traders, consider entering near $212.50 if price holds above the middle Bollinger Band and the 200-day moving average. A clear break above the $213.50 intraday high could target $215–$220, and a break above that would make the $230 strike a very real target. On the downside, if ABBV drops below $208.85, watch the $206.18 support level — it’s a key 30-day pivot that could stop further decline.

Volatility on the Horizon

This isn’t a one-way bet. With ABBV in a long-term range, a big move could shake things up. The legal case could go either way, and a surprise in the Q1 earnings could shift sentiment. But for now, the combination of options positioning, news flow, and technical levels suggests a near-term bias toward the upside — especially if the stock can hold above the $212.50 level.

If you're a swing trader or options player, this is a setup worth watching. The market is setting up for a potential breakout — and you don’t want to be caught unprepared.